Farmas USA

THLD

Vendida casi toda la posición a 4.40$. Comido por servido. Me quedo con unos cuantos décimos para la lotería.

THLD

Yo hice lo msimo... ¡hay que dejarse algo para la 'lotería' no sea que toque!

Cldx Abstract SNO

He añadido 5k mas a 7,50

NVAX

edito: y en cuanto esta pajara vuele cerca de los 9 suelto una buena tacada y profits a la saca

MNKD

Órden de compra a 2.5, buscando un ligero rebote,nada más. Pésimos resultados.

VALENCIA, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation(Nasdaq:MNKD) (TASE:MNKD) today reported financial results for the third quarter ended September 30, 2015.

For the three and nine months ended September 30, 2015, product shipments of Afrezza, our novel rapid-acting inhaled insulin therapy, were $4.1 million and $17.1 million, respectively, which we recorded as deferred product sales from our collaboration with Sanofi. For the quarter ended September 30, 2015, our portion of the loss sharing arrangement with Sanofi related to Afrezza was $14.7 million, which we subsequently financed by way of an advance under the loan facility with an affiliate of Sanofi after September 30, 2015. The amount currently outstanding under the Sanofi loan facility is now $43.7 million, which includes $0.8 million in paid-in-kind interest.

For the third quarter of 2015, total operating expenses decreased from $38.3 million to $26.0 million, a decline of 32.1%, compared to the same quarter in 2014, primarily due to Afrezza having moved out of clinical development into the commercial market. Additionally, non-cash stock compensation from the non-recurring achievement of performance and modification events in 2014 decreased in the third quarter of 2015 as compared to the third quarter of 2014. Research and development expenses decreased from $19.2 million to $6.3 million, a decrease of 67.2%, reflecting the transition from development to commercial activities. General and administrative expenses decreased from $19.1 million to $11.5 million, a reduction of 39.8%, mainly due to the decrease in non-cash stock compensation expense. Offsetting the total decrease of $20.5 million in R&D and G&A for the third quarter of 2015 were product manufacturing variance costs of $8.1 million. We did not recognize any product manufacturing costs in the third quarter of 2014 as we had not yet commenced commercialization of Afrezza.

For the first nine months of 2015, operating expenses were $71.8 million, a decline of 52.0% compared to the same period in 2014. Total research and development expenses for the nine months ended September 30, 2015 were $23.5 million, a decline of 71.6% compared to the same period in 2014, primarily due to reduced non-cash stock compensation expense resulting from the non-recurring achievement of performance and modification events in 2014 and in the first quarter of 2015. General and administrative expenses for the nine months ended September 30, 2015 were $32.6 million, a decrease of 51.2% compared to the same period in 2014, primarily due to reduced non-cash stock compensation expense resulting from the non-recurring achievement and modification events in 2014 and in the first quarter of 2015.

The net loss for the third quarter of 2015 was $31.9 million, or $0.08 per share, based on 405.2 million weighted average shares outstanding, compared with a net loss of $36.5 million, or $0.09 per share, based on 394.2 million weighted average shares outstanding for the third quarter of 2014. The number of common shares outstanding at September 30, 2015 was 418.3 million.

Cash and cash equivalents were $32.9 million at September 30, 2015, compared to $107.2 million in the second quarter of 2015. During the third quarter of 2015, we paid $64.3 million upon maturity of the 2015 notes and received $0.7 million in proceeds from warrant and option exercises, $7.2 million in payments from Sanofi for product shipments, and $12.2 million in net proceeds from our at-the-market sales facility. Currently, $30.1 million remains available to borrow under our amended loan arrangement with The Mann Group and $37.5 million of common stock remains available for sale under our at-the-market sales facility.

Read more: http://www.nasdaq.com/press-release/mannkind-corporation-reports-2015-third-quarter-financial-results-20151109-00160#ixzz3r0kRDYeW

Magnífico abstract! Vendido 1/3 a 15,40$ (casi un 30% bien rico) y el resto me lo guardo para el SNO como mínimo (del 19 al 22 de nov. para el que le interese) a ver si ese update de rindopepimut por fin la saca de los infiernos.

Por AT he vendido por fibo porque lleva una subida muy vertical en 2 días y de paso reduzco exposición, pero tiene una pinta bastante buena.

CLDX

NVAX
Si señor, a lo grande.
De cara a este año vista y pensando en una posible comercialización tras esa aprobación. Sería interesante saber cuando empieza a hacer la compañía el premarketing del producto, si ya tiene un sales manager, institutinal relationship manager,cuando se empieza a contratar al equipo de ventas, etc todo eso sería buena señal que una vez aprobado se comercializa y vende lo antes posible. Todas las compañías hacen esto generalmente antes de la aprobación del producto

Muy bueno!!! Espero verla mucho mas arriba y una aprobación vía fase 2 seria la ostia, Suerte.

solofarmas si sigues con DMPI Y IMUC también se han liberado los abstract del SNO.